Prevention of chemotherapy-induced ovarian damage

Fertility and Sterility

Volumn 105, Issue 1, 2016, Pages 20-29

  Roness, Hadassa ^a   Kashi, Oren ^a   Meirow, Dror ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

chemotherapy; Fertility preservation; follicle activation

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; BORTEZOMIB; CYTOTOXIC AGENT; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; MUELLERIAN INHIBITING FACTOR; MULTIDRUG RESISTANCE PROTEIN 1; SPHINGOSINE 1 PHOSPHATE; ANTINEOPLASTIC AGENT; PROTECTIVE AGENT;

APOPTOSIS; CHEMOTHERAPY; CHEMOTHERAPY INDUCED OVARIAN DAMAGE; HUMAN; HYPOPHYSIS GONAD SYSTEM; NANOENCAPSULATION; NONHUMAN; OVARY DISEASE; OVARY FOLLICLE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UPREGULATION; ANIMAL; CELL PROTECTION; CHEMICALLY INDUCED; DRUG DESIGN; DRUG EFFECTS; FEMALE; FERTILITY; INFERTILITY, FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; OVARY; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CYTOPROTECTION; DRUG DESIGN; FEMALE; FERTILITY; HUMANS; INFERTILITY, FEMALE; MOLECULAR TARGETED THERAPY; OVARIAN FOLLICLE; OVARY; PROTECTIVE AGENTS; SIGNAL TRANSDUCTION;

EID: 84961927526     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2015.11.043     Document Type: Review

References (100)

1. G. Bedoschi, and K. Oktay Current approach to fertility preservation by embryo cryopreservation Fertil Steril 99 2013 1496 1502
2. A. Cobo, V. Serra, N. Garrido, I. Olmo, A. Pellicer, and J. Remohí Obstetric and perinatal outcome of babies born from vitrified oocytes Fertil Steril 102 2014 1006 1015
3. The Practice Committee of the American Society for Reproductive Medicine Ovarian tissue cryopreservation: a committee opinion Fertil Steril 101 2014 1237 1243
4. K.A. Rodriguez-Wallberg, and K. Oktay Fertility preservation during cancer treatment: clinical guidelines Cancer Manag Res 6 2014 105 117
5. M. Shapira, H. Raanani, Y. Cohen, and D. Meirow Fertility preservation in young females with hematological malignancies Acta Haematol 132 2014 400 413
6. K. Chung, J. Donnez, E. Ginsburg, and D. Meirow Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients Fertil Steril 99 2013 1534 1542
7. S.J. Lee, L.R. Schover, A.H. Partridge, P. Patrizio, W.H. Wallace, K. Hagerty, and et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients J Clin Oncol 24 2006 2917 2931
8. M.M. Dolmans, V. Luyckx, J. Donnez, C.Y. Andersen, and T. Greve Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue Fertil Steril 99 2013 1514 1522
9. D. Meirow, H. Biederman, R.A. Anderson, and W.H. Wallace Toxicity of chemotherapy and radiation on female reproduction Clin Obstet Gynecol 53 2010 727 739
10. W. Fan Possible mechanisms of paclitaxel-induced apoptosis Biochem Pharmacol 57 1999 1215 1221
11. S. Stumm, A. Meyer, M. Lindner, G. Bastert, D. Wallwiener, and B. Guckel Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor Oncology 66 2004 101 111
12. F. Lopes, R. Smith, R.A. Anderson, and N. Spears Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing follicles Mol Hum Reprod 20 2014 948 959
13. E.C. Roti Roti, S.K. Leisman, D.H. Abbott, and S.M. Salih Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent PLoS One 7 2012 e42293
14. G.I. Perez, C.M. Knudson, L. Leykin, S.J. Korsmeyer, and J.L. Tilly Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction Nat Med 3 1997 1228 1232
15. G.I. Perez, X.J. Tao, and J.L. Tilly Fragmentation and death (a.k.a. apoptosis) of ovulated oocytes Mol Hum Reprod 5 1999 414 420
16. H. Bar-Joseph, I. Ben-Aharon, S. Rizel, S.M. Stemmer, M. Tzabari, and R. Shalgi Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes Reprod Toxicol 30 2010 566 572
17. L. Kalich-Philosoph, H. Roness, A. Carmely, M. Fishel, H. Ligumsky, S. Paglin, and et al. Cyclophosphamide triggers follicle activation causing ovarian reserve 'burn out'; AS101 prevents follicle loss and preserves fertility Sci Transl Med 2013 185
18. D. Adhikari, and K. Liu Molecular mechanisms underlying the activation of mammalian primordial follicles Endocr Rev 30 2009 438 464
19. K. Kawamura, Y. Cheng, N. Suzuki, M. Deguchi, Y. Sato, S. Takae, and et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment Proc Natl Acad Sci U S A 110 2013 17474 17479
20. J. Li, K. Kawamura, Y. Cheng, S. Liu, C. Klein, E.K. Duan, and et al. Activation of dormant ovarian follicles to generate mature eggs Proc Natl Acad Sci U S A 107 2010 10280 10284
21. M. McLaughlin, H.L. Kinnell, R.A. Anderson, and E.E. Telfer Inhibition of phosphatase and tensin homologue (PTEN) in human ovary in vitro results in increased activation of primordial follicles but compromises development of growing follicles Mol Hum Reprod 20 2014 736 744
22. H. Roness, Z. Gavish, Y. Cohen, and D. Meirow Ovarian follicle burnout: a universal phenomenon? Cell Cycle 12 2013 3245 3246
23. A.P. Sobinoff, B. Nixon, S.D. Roman, and E.A. McLaughlin Staying alive: PI3K pathway promotes primordial follicle activation and survival in response to 3-MC induced ovotoxicity Toxicol Sci 128 2012 258 271
24. D. Makarovsky, Y. Kalechman, T. Sonino, I. Freidkin, S. Teitz, M. Albeck, and et al. Tellurium compound AS101 induces PC12 differentiation and rescues the neurons from apoptotic death Ann N Y Acad Sci 1010 2003 659 666
25. Y. Kalechman, M. Albeck, M. Oron, D. Sobelman, M. Gurwith, G. Horwith, and et al. Protective and restorative role of AS101 in combination with chemotherapy Cancer Res 51 1991 1499 1503
26. Y. Kalechman, A. Shani, I. Sotnik-Barkai, M. Albeck, and B. Sredni The protective role of ammonium trichloro (dioxoethylene-O,O') tellurate in combination with several cytotoxic drugs acting by different mechanisms of action Cancer Res 53 1993 5962 5969
27. Y. Kalechman, I. Sotnik-Barkai, M. Albeck, and B. Sredni Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O')tellurate (AS101) Cancer Res 53 1993 1838 1844
28. B. Sredni, M. Albeck, G. Kazimirsky, and F. Shalit The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent Int J Immunopharmacol 14 1992 613 619
29. A.L. Durlinger, M.J. Gruijters, P. Kramer, B. Karels, H.A. Ingraham, M.W. Nachtigal, and et al. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary Endocrinology 143 2002 1076 1084
30. A.L. Durlinger, P. Kramer, B. Karels, F.H. de Jong, J.T. Uilenbroek, J.A. Grootegoed, and et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary Endocrinology 140 1999 5789 5796
31. Roness, H, Derech-Haim, S, Gavish, Z, Meirow, D. Anti-Mullerian c-treatment to prevent chemotherapy-induced activation and loss. ESHRE Annual Meeting, Lisbon, Portugal, June 14-17, 2015.
32. T. Utsunomiya, T. Tanaka, H. Utsunomiya, and N. Umesaki A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis Int J Oncol 32 2008 991 1000
33. R. Depalo, L. Nappi, G. Loverro, S. Bettocchi, M.L. Caruso, A.M. Valentini, and et al. Evidence of apoptosis in human primordial and primary follicles Hum Reprod 18 2003 2678 2682
34. Y. Morita, G.I. Perez, F. Paris, S.R. Miranda, D. Ehleiter, A. Haimovitz-Friedman, and et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy Nat Med 6 2000 1109 1114
35. T. Kurita, G.R. Cunha, S.J. Robboy, A.A. Mills, and R.T. Medina Differential expression of p63 isoforms in female reproductive organs Mech Dev 122 2005 1043 1055
36. E.K. Suh, A. Yang, A. Kettenbach, C. Bamberger, A.H. Michaelis, Z. Zhu, and et al. p63 protects the female germ line during meiotic arrest Nature 444 2006 624 628
37. G. Livera, B. Petre-Lazar, M.J. Guerquin, E. Trautmann, H. Coffigny, and R. Habert p63 null mutation protects mouse oocytes from radio-induced apoptosis Reproduction 135 2008 3 12
38. S. Gonfloni, L. Di Tella, S. Caldarola, S.M. Cannata, F.G. Klinger, C. Di Bartolomeo, and et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death Nat Med 15 2009 1179 1185
39. S.Y. Kim, M.H. Cordeiro, V.A. Serna, K. Ebbert, L.M. Butler, S. Sinha, and et al. Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network Cell Death Differ 20 2013 987 997
40. J.B. Kerr, K.J. Hutt, E.M. Michalak, M. Cook, C.J. Vandenberg, S.H. Liew, and et al. DNA Damage-Induced Primordial Follicle Oocyte Apoptosis and Loss of Fertility Require TAp63-Mediated Induction of Puma and Noxa Mol Cell 48 2012 343 352
41. R. Soleimani, E. Heytens, Z. Darzynkiewicz, and K. Oktay Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise Aging 3 2011 782 793
42. R. Albanese Induction and transmission of chemically induced chromosome aberrations in female germ cells Environ Mol Mutagen 10 1987 231 243
43. K. Dalberg, J. Eriksson, and L. Holmberg Birth outcome in women with previously treated breast cancer-a population-based cohort study from Sweden PLOS Med 9 2006 e336
44. D.M. Green, C.A. Sklar, J.D. Boice Jr., J.J. Mulvihill, J.A. Whitton, M. Stovall, and et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study J Clin Oncol 10 2009 2374 2381
45. D.M. Green, J.A. Whitton, M. Stovall, A.C. Mertens, S.S. Donaldson, F.B. Ruymann, and et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study Am J Obstet Gynecol 187 2002 1070 1080
46. B.A. Mueller, E.J. Chow, A. Kamineni, J.R. Daling, A. Fraser, C.L. Wiggins, and et al. Pregnancy outcomes in female childhood and adolescent cancer survivors: a linked cancer-birth registry analysis Arch Pediatr Adolesc Med 163 2009 879 886
47. K. Yoshida, and Y. Miki Enabling death by the Abl tyrosine kinase: mechanisms for nuclear shuttling of c-Abl in response to DNA damage Cell Cycle 4 2005 777 779
48. S. Kharbanda, P. Pandey, P.L. Morris, Y. Whang, Y. Xu, S. Sawant, and et al. Functional role for the c-Abl tyrosine kinase in meiosis I Oncogene 16 1998 1773 1777
49. S. Kharbanda, Z.M. Yuan, R. Weichselbaum, and D. Kufe Determination of cell fate by c-Abl activation in the response to DNA damage Oncogene 17 1998 3309 3318
50. J.B. Kerr, K.J. Hutt, M. Cook, T.P. Speed, A. Strasser, J.K. Findlay, and et al. Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib Nat Med 18 2012 1170 1172
51. E. Maiani, C. Di Bartolomeo, F.G. Klinger, S.M. Cannata, S. Bernardini, S. Chateauvieux, and et al. Reply to: Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib Nat Med 18 2012 1172 1174
52. S. Morgan, F. Lopes, C. Gourley, R.A. Anderson, and N. Spears Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin PLoS One 8 2013 e70117
53. Y. Sedletska, M.J. Giraud-Panis, and J.M. Malinge Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways Curr Med Chem Anticancer Agents 5 2005 251 265
54. C.O. Leong, N. Vidnovic, M.P. DeYoung, D. Sgroi, and L.W. Ellisen The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers J Clin Invest 117 2007 1370 1380
55. R. Soleimani, E. Heytens, and K. Oktay Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants PLoS One 6 2011 e19475
56. H. Kaya, R. Desdicioglu, M. Sezik, E. Ulukaya, O. Ozkaya, A. Yilmaztepe, and et al. Does sphingosine-1-phosphate have a protective effect on cyclophosphamide- and irradiation-induced ovarian damage in the rat model? Fertil Steril 89 2008 732 735
57. M.B. Zelinski, M.K. Murphy, M.S. Lawson, A. Jurisicova, K.Y. Pau, N.P. Toscano, and et al. In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates Fertil Steril 95 2011 1440 1445
58. K. Hancke, O. Strauch, C. Kissel, H. Gobel, W. Schafer, and D. Denschlag Sphingosine 1-phosphate protects ovaries from chemotherapy-induced damage in vivo Fertil Steril 87 2007 172 177
59. F. Li, V. Turan, S. Lierman, C. Cuvelier, P. De Sutter, and K. Oktay Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death Hum Reprod 29 2014 107 113
60. F. Paris, G.I. Perez, Z. Fuks, A. Haimovitz-Friedman, H. Nguyen, M. Bose, and et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring Nat Med 8 2002 901 902
61. M.F. Marcello, G. Nuciforo, R. Romeo, G. Di Dino, I. Russo, A. Russo, and et al. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment Cancer 66 1990 2099 2104
62. I. Ben-Aharon, I. Meizner, T. Granot, S. Uri, N. Hasky, S. Rizel, and et al. Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity Oncologist 17 2012 1386 1393
63. H. Bar-Joseph, I. Ben-Aharon, M. Tzabari, G. Tsarfaty, S.M. Stemmer, and R. Shalgi In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels PLoS One 6 2011 e23492
64. D. Meirow, J. Dor, B. Kaufman, A. Shrim, J. Rabinovici, E. Schiff, and et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury Hum Reprod 22 2007 1626 1633
65. G. Reeves Specific stroma in the cortex and medulla of the ovary. Cell types and vascular supply in relation to follicular apparatus and ovulation Obstet Gynecol 37 1971 832 844
66. M.E. Skaznik-Wikiel, M.M. McGuire, M. Sukhwani, J. Donohue, T. Chu, T.C. Krivak, and et al. Granulocyte colony-stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy Fertil Steril 99 2013 2045 2054
67. I. Solaroglu, J. Cahill, V. Jadhav, and J.H. Zhang A novel neuroprotectant granulocyte-colony stimulating factor Stroke 37 2006 1123 1128
68. P. Pastuszko, G.J. Schears, A. Pirzadeh, J. Kubin, W.J. Greeley, D.F. Wilson, and et al. Effect of granulocyte-colony stimulating factor on expression of selected proteins involved in regulation of apoptosis in the brain of newborn piglets after cardiopulmonary bypass and deep hypothermic circulatory arrest J Thorac Cardiovasc Surg 143 2012 1436 1442
69. Z. Blumenfeld, and M. von Wolff GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy Hum Reprod Update 14 2008 543 552
70. K. Ataya, L.V. Rao, E. Lawrence, and R. Kimmel Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys Biol Reprod 52 1995 365 372
71. E.A. Kishk, and M.H. Mohammed Ali Effect of a gonadotropin-releasing hormone analogue on cyclophosphamide-induced ovarian toxicity in adult mice Arch Gynecol Obstet 287 2013 1023 1029
72. X. Li, X. Kang, Q. Deng, J. Cai, and Z. Wang Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study Reprod Biol Endocrinol 11 2013 16
73. D. Meirow, G. Assad, J. Dor, and J. Rabinovici The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice Hum Reprod 19 2004 1294 1299
74. L. Del Mastro, L. Boni, A. Michelotti, T. Gamucci, N. Olmeo, S. Gori, and et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial JAMA 20 2011 269 276
75. A. Badawy, A. Elnashar, M. El-Ashry, and M. Shahat Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Fertil Steril 91 2009 694 697
76. E.A. Elgindy, D.O. El-Haieg, O.M. Khorshid, E.I. Ismail, M. Abdelgawad, H.N. Sallam, and et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial Obstet Gynecol 121 2013 78 86
77. B. Gerber, G. von Minckwitz, H. Stehle, T. Reimer, R. Felberbaum, N. Maass, and et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study J Clin Oncol 10 2011 2334 2341
78. P.N. Munster, A.P. Moore, R. Ismail-Khan, C.E. Cox, M. Lacevic, M. Gross-King, and et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer J Clin Oncol 10 2012 533 538
79. A. Sverrisdottir, M. Nystedt, H. Johansson, and T. Fornander Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial Breast Cancer Res Treat 117 2009 561 567
80. I. Demeestere, P. Brice, F.A. Peccatori, A. Kentos, I. Gaillard, P. Zachee, and et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial J Clin Oncol 31 2013 903 909
81. G. Song, H. Gao, and Z. Yuan Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial Med Oncol 30 2013 667
82. H.C. Moore, J.M. Unger, K.A. Phillips, F. Boyle, E. Hitre, D. Porter, and et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy N Engl J Med 372 2015 923 932
83. K. Oktay, K. Rodriguez-Wallberg, and P. Munster Ovarian protection during adjuvant chemotherapy N Engl J Med 372 2015 2268 2269
84. A.J. Hsueh, E.A. McGee, M. Hayashi, and S.Y. Hsu Hormonal regulation of early follicle development in the rat ovary Mol Cell Endocrinol 163 2000 95 100
85. J. Rabinovici, and R.B. Jaffe Development and regulation of growth and differentiated function in human and subhuman primate fetal gonads Endocr Rev 11 1990 532 557
86. Z. Blumenfeld How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embryo, oocytes, or ovaries Oncologist 12 2007 1044 1054
87. N. Hasky, S. Uri-Belapolsky, K. Goldberg, I. Miller, H. Grossman, S.M. Stemmer, and et al. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma? Hum Reprod 30 2015 1089 1101
88. H.I. Brunner, C.A. Silva, A. Reiff, G.C. Higgins, L. Imundo, C.B. Williams, and et al. Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus Arthritis Rheumatol 67 2015 1377 1385
89. Z. Blumenfeld, and E. Dann GnRH agonist for the prevention of chemotherapy-induced ovarian failure in lymphoma J Clin Oncol 31 2013 3721
90. K. Kiyomiya, S. Matsuo, and M. Kurebe Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex Cancer Res 61 2001 2467 2471
91. E.C. Roti Roti, A.K. Ringelstetter, J. Kropp, D.H. Abbott, and S.M. Salih Bortezomib prevents acute doxorubicin ovarian insult and follicle demise, improving the fertility window and pup birth weight in mice PLoS One 9 2014 e108174
92. A.T. Fojo, K. Ueda, D.J. Slamon, D.G. Poplack, M.M. Gottesman, and I. Pastan Expression of a multidrug-resistance gene in human tumors and tissues Proc Natl Acad Sci U S A 84 1987 265 269
93. E.R. Lepper, K. Nooter, J. Verweij, M.R. Acharya, W.D. Figg, and A. Sparreboom Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2 Pharmacogenomics 6 2005 115 138
94. S.M. Salih Retrovirus-mediated multidrug resistance gene (MDR1) overexpression inhibits chemotherapy-induced toxicity of granulosa cells Fertil Steril 95 2011 1390 1396
95. L.M. Brayboy, N. Oulhen, J. Witmyer, J. Robins, S. Carson, and G.M. Wessel Multidrug-resistant transport activity protects oocytes from chemotherapeutic agents and changes during oocyte maturation Fertil Steril 100 2013 1428 1435
96. E. Tahover, Y.P. Patil, and A.A. Gabizon Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes Anticancer Drugs 26 2015 241 258
97. R.W. Ahn, S.L. Barrett, M.R. Raja, J.K. Jozefik, L. Spaho, H. Chen, and et al. Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo PLoS One 8 2013 e58491
98. A. Jurisicova, H.J. Lee, S.G. D'Estaing, J. Tilly, and G.I. Perez Molecular requirements for doxorubicin-mediated death in murine oocytes Cell Death Differ 13 2006 1466 1474
99. A. Akdemir, B. Zeybek, L. Akman, A.M. Ergenoglu, A.O. Yeniel, O. Erbas, and et al. Granulocyte-colony stimulating factor decreases the extent of ovarian damage caused by cisplatin in an experimental rat model J Gynecol Oncol 25 2014 328 333
100. H Roness, L Kalich-Philosoph, and D Meirow Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents Hum Reprod Update 20 2014 759 774